DE69229482T2 - Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor - Google Patents

Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor

Info

Publication number
DE69229482T2
DE69229482T2 DE69229482T DE69229482T DE69229482T2 DE 69229482 T2 DE69229482 T2 DE 69229482T2 DE 69229482 T DE69229482 T DE 69229482T DE 69229482 T DE69229482 T DE 69229482T DE 69229482 T2 DE69229482 T2 DE 69229482T2
Authority
DE
Germany
Prior art keywords
chain
human
region
antibody
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69229482T
Other languages
German (de)
English (en)
Other versions
DE69229482D1 (de
Inventor
Mary Bendig
Steven Jones
Jose Saldanha
Koh Sato
Masayuki Tsuchiya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26370596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69229482(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP3095476A external-priority patent/JPH05236966A/ja
Priority claimed from JP4032084A external-priority patent/JPH05227970A/ja
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69229482D1 publication Critical patent/DE69229482D1/de
Publication of DE69229482T2 publication Critical patent/DE69229482T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69229482T 1991-04-25 1992-04-24 Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor Expired - Lifetime DE69229482T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP3095476A JPH05236966A (ja) 1991-04-25 1991-04-25 ヒトインターロイキン−６レセプターに対するマウスモノクローナル抗体の可変領域をコードするｄｎａ
JP4032084A JPH05227970A (ja) 1992-02-19 1992-02-19 ヒトインターロイキン−６受容体に対する再構成ヒト抗体
PCT/JP1992/000544 WO1992019759A1 (fr) 1991-04-25 1992-04-24 Anticorps humains reconstitues diriges contre un recepteur de l'interleukine 6 humaine

Publications (2)

Publication Number Publication Date
DE69229482D1 DE69229482D1 (de) 1999-07-29
DE69229482T2 true DE69229482T2 (de) 1999-11-18

Family

ID=26370596

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69229482T Expired - Lifetime DE69229482T2 (de) 1991-04-25 1992-04-24 Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor
DE122009000019C Pending DE122009000019I1 (de) 1991-04-25 1992-04-24 Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE122009000019C Pending DE122009000019I1 (de) 1991-04-25 1992-04-24 Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor

Country Status (16)

Country Link
US (3) US5795965A (index.php)
EP (1) EP0628639B1 (index.php)
JP (6) JP3370324B2 (index.php)
KR (1) KR100249937B1 (index.php)
AT (1) ATE181575T1 (index.php)
AU (2) AU668349B2 (index.php)
DE (2) DE69229482T2 (index.php)
DK (1) DK0628639T3 (index.php)
ES (1) ES2134212T3 (index.php)
GR (1) GR3031174T3 (index.php)
HU (1) HU218140B (index.php)
LU (1) LU91556I2 (index.php)
NL (1) NL300383I2 (index.php)
RU (1) RU2139351C1 (index.php)
TW (1) TW205553B (index.php)
WO (1) WO1992019759A1 (index.php)

Families Citing this family (338)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472693A (en) * 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
TW458985B (en) * 1993-05-31 2001-10-11 Chugai Pharmaceutical Co Ltd Reconstructed human antibody against human interleukin-6
JP3741221B2 (ja) * 1993-08-24 2006-02-01 エスアールディー ファーマシューティカルズ，インコーポレイテッド 組換えヒト型化抗ヒト免疫不全ウィルス抗体
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
EP0729976A1 (en) * 1993-11-19 1996-09-04 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human medulloblastomatous cell
WO1995029690A1 (en) * 1994-04-29 1995-11-09 The Trustees Of The University Of Pennsylvania Biologically active peptides and methods of identifying the same
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
CN101361972B (zh) * 1994-10-07 2011-05-25 中外制药株式会社 以il-6拮抗剂作为有效成分治疗慢性类风湿性关节炎
CZ298790B6 (cs) * 1994-10-21 2008-01-30 Kishimoto@Tadamitsu Farmaceutický prípravek pro prevenci nebo lécení kachexie
JP4540132B2 (ja) * 1995-02-13 2010-09-08 中外製薬株式会社 Ｉｌ−６レセプター抗体を含んでなる筋蛋白分解抑制剤
US6692742B1 (en) 1996-06-27 2004-02-17 Chugai Seiyaku Kabushiki Kaisha Remedies for myeloma to be used together with nitrogen mustard antitumor agents
SK40599A3 (en) 1996-09-26 2000-06-12 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
KR20000070989A (ko) * 1997-02-12 2000-11-25 나가야마 오사무 임파구계 종양의 치료제
AU736282B2 (en) 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
UA74130C2 (uk) 1997-05-15 2005-11-15 Чугаі Сейяку Кабусікі Кайся ЗАСТОСУВАННЯ АНТИТІЛА ПРОТИ БІЛКА, СПОРІДНЕНОГО З ПАРАТИРЕОЇДНИМ ГОРМОНОМ (PTHrP), АБО ЙОГО ФУНКЦІОНАЛЬНО АКТИВНОГО ФРАГМЕНТА І/АБО ЙОГО МОДИФІКОВАНОГО ФРАГМЕНТА ДЛЯ ВИРОБНИЦТВА ЛІКАРСЬКОГО ЗАСОБУ ДЛЯ ПРОФІЛАКТИКИ АБО ЛІКУВАННЯ КАХЕКСІЇ
PT1004315E (pt) * 1997-08-15 2008-07-09 Chugai Pharmaceutical Co Ltd Profilácticos e/ou medicamentos contendo anticorpos neutralizantes anti-receptor de il-6 para reduzir a excreção de proteínas urinárias no lúpus eritematoso sistémico
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
KR100407811B1 (ko) 1998-03-17 2003-12-01 츄가이 세이야꾸 가부시키가이샤 인터루킨-6 안타고니스트를 유효성분으로서 함유하는 염증성 장질환의 예방 또는 치료제
EP1069185B1 (en) 1998-04-03 2011-06-08 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
ES2276525T3 (es) * 1998-08-24 2007-06-16 Chugai Seiyaku Kabushiki Kaisha Preventivos o remedios para la pancreatitis que contienen anticuerpos anti-receptor il-6 como ingrediente activo.
ATE338120T2 (de) 1998-11-27 2006-09-15 Ucb Sa Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
WO2001016166A2 (en) * 1999-08-27 2001-03-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Polypeptides, comprising il-6 ligand-binding receptor domains, and related nucleic acids, antibodies, compositions, and methods of use
BR0014667A (pt) 1999-10-01 2002-07-02 Chugai Pharmaceutical Co Ltd Prevenção e tratamento de doenças relacionadas à coagulação sanguìnea
GB0002666D0 (en) 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
DE60137417D1 (de) 2000-04-28 2009-03-05 Chugai Pharmaceutical Co Ltd Zellproliferation-inhibitoren
EP1314437B1 (en) 2000-08-11 2014-06-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
EP2351838A1 (en) 2000-10-20 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Crosslinking agonistic antibodies
KR20030055274A (ko) 2000-10-20 2003-07-02 츄가이 세이야꾸 가부시키가이샤 저분자화 트롬보포에틴 아고니스트 항체
EP1327681A4 (en) 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Degraded agonist antibodies
DK1334731T3 (da) 2000-10-25 2008-05-26 Chugai Pharmaceutical Co Ltd Forebyggende eller terapeutisk middel mod psoriasis omfattende anti-IL-6-receptorantistof som aktiv bestanddel
WO2002036165A1 (fr) * 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang
WO2002036164A1 (en) * 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
US7931897B2 (en) 2001-02-07 2011-04-26 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for hematopoietic tumors
WO2002098370A2 (en) * 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
US7332289B2 (en) 2001-03-09 2008-02-19 Chugai Seiyaku Kabushiki Kaisha Method of purifying protein
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
EP1382964A4 (en) 2001-04-17 2009-06-10 Chugai Pharmaceutical Co Ltd METHOD FOR TENSID QUANTIFICATION
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
CA2447139C (en) * 2001-05-11 2013-11-19 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
AU2003211991B2 (en) * 2002-02-14 2008-08-21 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution formulations
GB0208041D0 (en) * 2002-04-08 2002-05-22 Lonza Biologics Plc Method of culturing animal cells
US20050255103A1 (en) * 2002-04-25 2005-11-17 Chugai Seiyaku Kabushiki Kaisha Remedy for lung cancer
WO2003102157A2 (en) 2002-06-03 2003-12-11 Genentech, Inc. Synthetic antibody phage libraries
JP4489591B2 (ja) 2002-08-27 2010-06-23 中外製薬株式会社 タンパク質溶液製剤の安定化方法
AU2002338020A1 (en) 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
WO2004024752A1 (ja) 2002-09-11 2004-03-25 Chugai Seiyaku Kabushiki Kaisha タンパク質精製方法
HRP20050837A2 (en) 2003-02-24 2005-12-31 Keio University Chugai Seiyaku Kabushiki Kaisha Remedy for spinal injury containing interleukin-6 antagonists
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
NO345763B1 (no) * 2003-06-16 2021-07-19 Celltech R&D Inc Immunogen og antistoffer spesifikke for sklerostin, samt farmasøytiske preparater for å øke benmineralisering.
US7709615B2 (en) 2003-07-15 2010-05-04 Chugai Seiyaku Kabushiki Kaisha Polynucleotides encoding anti-ganglioside antibodies
MXPA06003768A (es) 2003-10-17 2006-06-23 Chugai Pharmaceutical Co Ltd Agente terapeutico para el mesotelioma.
KR20060123413A (ko) 2003-12-03 2006-12-01 추가이 세이야쿠 가부시키가이샤 포유류 β 액틴 프로모터를 이용한 발현계
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
US8617550B2 (en) 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
CA2555688C (en) * 2004-02-11 2011-11-08 Warner-Lambert Company Llc Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
WO2005079479A2 (en) * 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
WO2005090405A1 (ja) 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha インターロイキン－６受容体に対するヒト型化抗体のサブタイプ
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
EP1810980A1 (en) * 2004-10-28 2007-07-25 Osaka University Interleukin-6 inhibitors
ES2535230T3 (es) 2005-01-05 2015-05-06 Chugai Seiyaku Kabushiki Kaisha Método de cultivo celular y utilización del mismo
PT1859793E (pt) * 2005-02-28 2011-07-05 Eisai R&D Man Co Ltd Uso combinado inovador de um composto de sulfonamida no tratamento oncológico
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
EP1908482B1 (en) 2005-06-10 2017-09-06 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
CN105017423B (zh) * 2005-08-11 2019-06-04 阿皮·马托西安-罗杰斯 用于自身免疫性疾病治疗和诊断的TCR-V-β相关肽
US8470316B2 (en) 2005-10-14 2013-06-25 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
RU2450830C2 (ru) 2005-10-21 2012-05-20 Чугаи Сейяку Кабусики Кайся Средства для лечения кардиопатии
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007055378A1 (ja) 2005-11-14 2007-05-18 Cell Signals Inc. 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (ja) 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
CA2637917C (en) 2006-01-27 2015-11-24 Keio University Therapeutic agents for diseases involving choroidal neovascularization
US8546329B2 (en) 2006-03-22 2013-10-01 Chugai Seiyaku Kabushiki Kaisha Erythropoietin solution preparation
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CN101495146B (zh) 2006-04-07 2012-10-17 国立大学法人大阪大学 肌肉再生促进剂
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
MX2008014842A (es) * 2006-05-25 2009-02-17 Glaxo Group Ltd Anticuerpos humanizados contra interleuquina-18 modificados.
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
PL2041177T3 (pl) 2006-06-02 2012-09-28 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
CA2655362A1 (en) 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
RU2412203C2 (ru) 2006-06-21 2011-02-20 Онкотерапи Сайенс, Инк. Направленные на опухоль моноклональные антитела против fzd10 и их применение
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
US20080081041A1 (en) * 2006-09-29 2008-04-03 Jeffrey Nemeth Method of Using IL6 Antagonists with Mitoxantrone for Prostate Cancer
KR101508019B1 (ko) 2007-01-23 2015-04-06 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 만성 거부반응 억제제
US8088617B2 (en) 2007-01-24 2012-01-03 Oncomed Pharmaceuticals, Inc. Antibodies that bind the glutamate ligand binding region of Notch1
EP2126127B1 (en) 2007-01-25 2016-09-28 Dana-Farber Cancer Institute, Inc. Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
CL2008000719A1 (es) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US8404235B2 (en) * 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8062864B2 (en) * 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
CN101868477A (zh) * 2007-05-21 2010-10-20 奥尔德生物制药公司 新型兔抗体人源化方法和人源化的兔抗体
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
EP3187506B1 (en) * 2007-05-21 2019-03-27 AlderBio Holdings LLC Antibodies to il-6 and use thereof
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
JP5142265B2 (ja) * 2007-05-28 2013-02-13 独立行政法人産業技術総合研究所 抗モータリン抗体のパラトープ及びエピトープ
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
JP5424330B2 (ja) * 2007-07-26 2014-02-26 国立大学法人大阪大学 インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
WO2009018453A1 (en) 2007-07-31 2009-02-05 Lifescan, Inc. Differentiation of human embryonic stem cells
US9283276B2 (en) 2007-08-14 2016-03-15 Ludwig Institute For Cancer Research Ltd. Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
EP3059246B1 (en) 2007-09-26 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
CL2008002885A1 (es) 2007-09-26 2010-07-02 Chugai Pharmaceutical Co Ltd Anticuerpo anti-receptor de interleucina-6 (il-6); y composicion farmaceutica que lo comprende
EP4368721A3 (en) 2007-09-26 2024-12-18 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
KR101601986B1 (ko) 2007-10-02 2016-03-17 추가이 세이야쿠 가부시키가이샤 인터류킨 6 수용체 저해제를 유효 성분으로 하는 이식편대숙주병 치료제
MX2010004007A (es) * 2007-10-15 2010-06-15 Chugai Pharmaceutical Co Ltd Metodo para la produccion de un anticuerpo.
CN101878298B (zh) 2007-11-27 2017-08-15 生命扫描有限公司 人胚胎干细胞的分化
ES2834741T3 (es) * 2007-12-05 2021-06-18 Chugai Pharmaceutical Co Ltd Anticuerpo anti-NR10 y uso del mismo
JPWO2009075344A1 (ja) 2007-12-12 2011-04-28 独立行政法人国立がん研究センター Ｍ−ｃｓｆ受容体を分子標的とするｍｌｌ白血病及びｍｏｚ白血病治療剤、およびその利用
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009095489A2 (en) * 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2009105570A2 (en) 2008-02-21 2009-08-27 Centocor Ortho Biotech Inc. Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
KR20220162801A (ko) 2008-04-11 2022-12-08 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
WO2009134776A2 (en) * 2008-04-29 2009-11-05 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
AU2009246430B2 (en) 2008-05-13 2015-07-02 Novimmune S.A. Anti-IL-6/IL-6R antibodies and methods of use thereof
MX2010013239A (es) 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
SG191625A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN102256623A (zh) 2008-06-05 2011-11-23 独立行政法人国立癌症研究中心 神经浸润抑制剂
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
ES2697798T3 (es) 2008-06-30 2019-01-28 Janssen Biotech Inc Diferenciación de células madre pluripotentes
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
EP2307051B1 (en) 2008-07-08 2015-02-11 OncoMed Pharmaceuticals, Inc. Notch-binding agents and antagonists and methods of use thereof
RU2011104348A (ru) 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US9234178B2 (en) 2008-10-31 2016-01-12 Janssen Biotech, Inc. Differentiation of human pluripotent stem cells
US9969973B2 (en) 2008-11-20 2018-05-15 Janssen Biotech, Inc. Methods and compositions for cell attachment and cultivation on planar substrates
CA2744234C (en) 2008-11-20 2018-11-06 Centocor Ortho Biotech Inc. Pluripotent stem cell culture on micro-carriers
US8323649B2 (en) * 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
TWI646193B (zh) 2009-03-19 2019-01-01 中外製藥股份有限公司 抗體恆定區域改變體
BRPI1013877A2 (pt) 2009-04-10 2017-08-15 Ablynx Nv Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r
WO2010115995A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
US20110008766A1 (en) * 2009-05-01 2011-01-13 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
AU2010248365A1 (en) 2009-05-15 2011-12-22 Chugai Seiyaku Kabushiki Kaisha Anti-AXL antibody
SG177481A1 (en) 2009-07-20 2012-02-28 Janssen Biotech Inc Differentiation of human embryonic stem cells
US20120183539A1 (en) 2009-07-31 2012-07-19 Shin Maeda Cancer Metastasis Inhibitor
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
EP2481752B1 (en) 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
CN102666875A (zh) * 2009-10-15 2012-09-12 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
MX2012004682A (es) * 2009-10-26 2012-09-07 Hoffmann La Roche Metodo para la produccion de una inmunoglobulina glicosilada.
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
US9468676B2 (en) 2009-11-24 2016-10-18 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
CN102781964B (zh) 2009-12-28 2015-11-25 肿瘤疗法科学股份有限公司 抗cdh3抗体及其用途
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
WO2011088215A2 (en) * 2010-01-13 2011-07-21 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
SG10201501503VA (en) 2010-03-01 2015-04-29 Janssen Biotech Inc Methods for purifying cells derived from pluripotent stem cells
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
EP2543388A4 (en) 2010-03-04 2013-11-27 Dainippon Sumitomo Pharma Co MEDICINAL PRODUCT FOR INFLAMMATORY ENDURANCE
ES2993140T3 (en) 2010-04-02 2024-12-23 Amunix Pharmaceuticals Inc Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2011128096A1 (en) 2010-04-16 2011-10-20 Roche Diagnostics Gmbh Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
CN107338217B (zh) 2010-05-12 2021-02-09 詹森生物科技公司 人胚胎干细胞的分化
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
WO2011149046A1 (ja) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター 膵癌治療剤
ES2932398T3 (es) 2010-05-28 2023-01-18 Chugai Pharmaceutical Co Ltd Potenciador de la respuesta de las células T antitumorales
CN103025354A (zh) 2010-06-02 2013-04-03 大日本住友制药株式会社 自身免疫疾病和变应性疾病的治疗药
US20120009177A1 (en) 2010-06-07 2012-01-12 Roche Molecular Systems, Inc. Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
AR082461A1 (es) 2010-08-03 2012-12-12 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
KR101851956B1 (ko) 2010-08-31 2018-04-25 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
US9238690B2 (en) 2010-10-29 2016-01-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
SG189929A1 (en) 2010-10-29 2013-06-28 Immunogen Inc Novel egfr-binding molecules and immunoconjugates thereof
MX2013005024A (es) 2010-11-08 2013-11-21 Chugai Pharmaceutical Co Ltd Anticuerpo anti-il-6 receptor administrado subcutaneamente.
TWI629355B (zh) 2010-11-17 2018-07-11 中外製藥股份有限公司 具有替代血液凝固第ｖｉｉｉ因子之功能的多重專一性抗原結合分子
WO2012071554A2 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
RU2721279C2 (ru) 2011-01-28 2020-05-18 Санофи Байотекнолоджи Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов
EP2679681B2 (en) 2011-02-25 2023-11-15 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific FC antibody
EP2681242B1 (en) 2011-03-01 2018-01-24 Amgen Inc. Sclerostin and dkk-1 bispecific binding agents
US9145457B2 (en) 2011-03-25 2015-09-29 Amgen Inc. Sclerostin antibody crystals and formulations thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9309305B2 (en) 2011-06-10 2016-04-12 National Research Council Of Canada Anti-ricin antibodies and uses thereof
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
IL276534B2 (en) 2011-06-28 2025-11-01 Inhibrx Inc Methods for purifying serpin containing fusion proteins
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
WO2013017656A1 (en) 2011-08-02 2013-02-07 Medizinische Universität Wien Antagonists of ribonucleases for treating obesity
AU2012290083B2 (en) 2011-08-04 2017-07-20 Amgen Inc. Method for treating bone gap defects
WO2013017691A1 (en) 2011-08-04 2013-02-07 Medizinische Universität Innsbruck Cahgt1p inhibitors for use in the treatment of candidiasis
SG11201400260TA (en) 2011-09-01 2014-03-28 Chugai Pharmaceutical Co Ltd Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK2747782T3 (en) 2011-09-23 2018-04-23 Ablynx Nv Long-term inhibition of interleukin-6-mediated signal transmission
DE102011083811A1 (de) * 2011-09-30 2013-04-04 Airbus Operations Gmbh Sitzvorrichtung für ein Luft- oder Raumfahrzeug
EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
LT3682905T (lt) 2011-10-03 2022-02-25 Modernatx, Inc. Modifikuoti nukleozidai, nukleotidai ir nukleorūgštys bei jų naudojimas
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
WO2013059548A1 (en) 2011-10-19 2013-04-25 Sanofi Compositions and methods for treating cancer using jak2 inhibitor
JP6184965B2 (ja) 2011-10-28 2017-08-23 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド ポリペプチド構築物およびその使用
JO3370B1 (ar) 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
CN104066481A (zh) 2011-11-21 2014-09-24 伊缪诺金公司 利用egfr抗体细胞毒性剂缀合物治疗抗egfr疗法的肿瘤的方法
AU2011382454B2 (en) 2011-11-30 2017-02-23 Abbvie Biotechnology Ltd Vectors and host cells comprising a modified SV40 promoter for protein expression
CN109276713A (zh) * 2011-12-13 2019-01-29 诺帝克纳诺维科特股份公司 嵌合的治疗性抗-cd37抗体hh1
PT2791160T (pt) 2011-12-16 2022-07-04 Modernatx Inc Composições arnm modificado
KR102090751B1 (ko) 2011-12-22 2020-03-19 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 단일 인슐린 호르몬 양성 세포로의 분화
CA2858974A1 (en) 2011-12-28 2013-07-04 Amgen Inc. Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
UY34558A (es) 2011-12-30 2013-07-31 Abbvie Inc Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
JP6487839B2 (ja) 2012-03-15 2019-03-20 ヤンセン バイオテツク，インコーポレーテツド ヒト抗ｃｄ２７抗体、方法、及び使用
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
CA2865676C (en) 2012-04-17 2020-03-10 Stefan Klostermann Method for the expression of polypeptides using modified nucleic acids
KR101510831B1 (ko) * 2012-05-11 2015-04-10 가톨릭대학교 산학협력단 항 ｉｌ-６ｒ 및 ｔｎｆｒ２을 포함하는 이중특이적 단백질을 발현하는 미니서클 벡터를 포함하는 줄기세포 치료제
KR101510830B1 (ko) 2012-05-11 2015-04-10 가톨릭대학교 산학협력단 생리활성 단백질을 발현하는 미니서클을 이용하여 형질전환된 줄기세포를 통한 치료법
KR101510302B1 (ko) * 2012-05-11 2015-04-10 가톨릭대학교 산학협력단 Ｉｌ-６ 수용체를 표적으로 하는 항체가 생성되도록 미니서클 벡터를 통해 형질전환된 줄기세포 치료제
KR102285014B1 (ko) 2012-06-08 2021-08-03 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 췌장 내분비 세포로의 분화
US9925260B2 (en) 2012-07-05 2018-03-27 Ucb Pharma S.A. Treatment for bone diseases
JP6282591B2 (ja) 2012-09-13 2018-02-21 中外製薬株式会社 遺伝子ノックイン非ヒト動物
US9487590B2 (en) 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
AR093311A1 (es) 2012-11-01 2015-05-27 Abbvie Inc Inmunoglobulinas de dominio variable dual contra el factor de crecimiento endotelial vascular (vegf) y el ligando involucrado en la señalizacion celula a celula a traves del receptor notch (dll4)
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
DK2938722T3 (da) 2012-12-31 2022-02-14 Janssen Biotech Inc Suspension og klyngedannelse af humane pluripotente celler til differentiering til endokrine pankreasceller
US10344264B2 (en) 2012-12-31 2019-07-09 Janssen Biotech, Inc. Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
CN105073979B (zh) 2012-12-31 2020-03-06 詹森生物科技公司 使用hb9调节子使人胚胎干细胞分化为胰腺内分泌细胞的方法
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
PL3677591T3 (pl) 2013-04-29 2023-06-26 Teva Pharmaceuticals Australia Pty Ltd Przeciwciała anty-cd38 i fuzje z interferonem alfa-2b o osłabionej aktywności
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
EP3017303B1 (en) 2013-07-04 2018-01-03 F.Hoffmann-La Roche Ag Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples
MX382731B (es) 2013-09-27 2025-03-13 Chugai Pharmaceutical Co Ltd Metodo para producir heteromultimeros de polipeptidos.
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
EP3088517B1 (en) 2013-12-26 2023-11-01 Mitsubishi Tanabe Pharma Corporation Human anti-il-33 neutralizing monoclonal antibody
JP6722455B2 (ja) 2013-12-27 2020-07-15 中外製薬株式会社 等電点の低い抗体の精製方法
EP2898896A1 (en) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
WO2015116852A1 (en) 2014-01-29 2015-08-06 Regeneron Pharmaceuticals, Inc. Methods for treating rheumatoid arthritis by administering an il-6r antibody
PE20211798A1 (es) 2014-03-21 2021-09-13 Abbvie Inc Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
JP6588969B2 (ja) 2014-05-16 2019-10-09 ヤンセン バイオテツク，インコーポレーテツド 膵内分泌細胞内のｍａｆａ発現を強化するための小分子の使用
JP6858559B2 (ja) 2014-08-20 2021-04-14 中外製薬株式会社 蛋白質溶液の粘度測定方法
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CN107074954A (zh) 2014-10-21 2017-08-18 埃博灵克斯股份有限公司 Il‑6r相关疾病的治疗
AU2015337858B2 (en) 2014-10-29 2020-09-24 Teva Pharmaceuticals Australia Pty Ltd. Interferon alpha2b variants
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
US11384350B2 (en) 2014-12-15 2022-07-12 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing
WO2016100232A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
WO2016098357A1 (en) 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
TWI725847B (zh) 2014-12-19 2021-04-21 日商中外製藥股份有限公司 抗c5抗體及使用方法
AU2016216079A1 (en) 2015-02-05 2017-07-13 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, Fc region variants, IL-8-binding antibodies, and uses therof
EP4269440A3 (en) 2015-02-27 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
AR104050A1 (es) 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JP6875683B2 (ja) 2015-05-19 2021-05-26 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症（ｍｓ）患者の新規治療適用判断方法
US11174317B2 (en) 2015-06-04 2021-11-16 National Center Of Neurology And Psychiatry Therapeutic agent for mental illness comprising IL-6 inhibitor as active ingredient
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
KR20180034672A (ko) 2015-08-18 2018-04-04 리제너론 파아마슈티컬스, 인크. 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체
CA3003874A1 (en) 2015-11-03 2017-05-11 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
WO2017115773A1 (ja) 2015-12-28 2017-07-06 中外製薬株式会社 Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
WO2017147169A1 (en) 2016-02-22 2017-08-31 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
TW202214700A (zh) 2016-03-14 2022-04-16 日商中外製藥股份有限公司 用於癌之治療的細胞傷害誘導治療劑
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
MY200833A (en) 2016-04-28 2024-01-17 Chugai Pharmaceutical Co Ltd Antibody-Containing Preparation
KR102538749B1 (ko) 2016-08-05 2023-06-01 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
CA3039136A1 (en) 2016-09-02 2018-03-08 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
RU2019112680A (ru) 2016-09-27 2020-10-29 Фрезениус Каби Дойчланд Гмбх Жидкая фармацевтическая композиция
KR102051177B1 (ko) * 2016-10-19 2019-12-17 주식회사 엘지화학 전압 분배를 이용한 스위치 진단 장치 및 방법
ES2882181T3 (es) 2016-10-31 2021-12-01 Fresenius Kabi Deutschland Gmbh Composición farmacéutica líquida
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
EP3596175A4 (en) 2017-03-17 2021-01-13 The Ohio State Innovation Foundation NANOPARTICLES FOR THE ADMINISTRATION OF CHEMOPREVENTIVE AGENTS
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
CN107098969B (zh) * 2017-06-28 2018-10-12 武汉波睿达生物科技有限公司 一种治疗hiv感染的嵌合抗原受体的重组基因构建及其应用
BR112020003458A2 (pt) 2017-08-31 2020-08-25 Mitsubishi Tanabe Pharma Corporation agente terapêutico contendo antagonistas il-33 para endometriose
BR112020004336A2 (pt) 2017-09-13 2020-09-08 Jiangsu Hengrui Medicine Co., Ltd. anticorpo il-6r e fragmento de ligação de antígeno do mesmo e uso médico
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
CN119161488A (zh) 2017-11-01 2024-12-20 中外制药株式会社 具有降低的生物活性的抗体变体和同种型
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
IL276911B2 (en) 2018-03-30 2025-04-01 Amgen Inc Variants of the carboxylation rate of antibodies
ES2986389T3 (es) 2018-05-21 2024-11-11 Chugai Pharmaceutical Co Ltd Formulación liofilizada sellada en un vial de vidrio
CN115636141A (zh) 2018-05-28 2023-01-24 中外制药株式会社 填充喷嘴
BR112021003206A2 (pt) 2018-08-29 2021-05-25 Regeneron Pharmaceuticals, Inc. métodos e composições para tratar indivíduos com artrite reumatoide
US20220096548A1 (en) * 2019-01-07 2022-03-31 Hunan Siweikang Therapeutics Co. Ltd. Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy
SG11202107735SA (en) 2019-01-31 2021-08-30 Sanofi Biotechnology Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
BR112021017702A2 (pt) 2019-03-29 2021-11-16 Chugai Pharmaceutical Co Ltd Inibidor contendo anticorpo anti-receptor de il-6 para inibição de deterioração da função bhe
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
CA3136398A1 (en) 2019-04-10 2020-10-15 Chugai Seiyaku Kabushiki Kaisha Method for purifying fc region-modified antibody
US20220204608A1 (en) 2019-04-17 2022-06-30 Hiroshima University Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
CA3137909A1 (en) 2019-04-24 2020-10-29 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
EP3976644A4 (en) 2019-05-31 2022-12-14 The Johns Hopkins University BI-SPECIFIC LIAISONS
KR20230061198A (ko) 2019-06-04 2023-05-08 사노피 바이오테크놀로지 류마티스성 관절염을 갖는 대상체에서 통증을 치료하기 위한 조성물 및 방법
EP3986481A2 (en) 2019-06-20 2022-04-27 Takeda Pharmaceutical Company Limited Method of treatment with viral-based gene therapy
CN110483640B (zh) * 2019-07-16 2020-05-01 北京汇智和源生物技术有限公司 白介素-6r的人源化单克隆抗体、其编码基因及应用
BR112022017574A2 (pt) 2020-03-03 2022-11-16 Twentyeight Seven Inc Compostos que têm como alvo proteínas de ligação ao rna ou proteínas modificadoras de rna
US20230125415A1 (en) 2020-03-23 2023-04-27 Genentech, Inc. Biomarkers for predicting response to il-6 antagonist in covid-19 pneumonia
WO2021194860A1 (en) 2020-03-23 2021-09-30 Genentech, Inc. Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
WO2021194865A1 (en) 2020-03-23 2021-09-30 Genentech, Inc. Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist
WO2021211006A1 (en) 2020-04-13 2021-10-21 Federal State Budgetary Institution Center Of Biomedical Technologies Of Federal Medical And Biological Agency Inhaled hexapeptide for treating interleukin-6 related respiratory diseases
JP2023520249A (ja) 2020-05-15 2023-05-16 エフ． ホフマン－ラ ロシュ アーゲー 非経口タンパク質溶液中の可視粒子形成の防止方法
US20230167182A1 (en) * 2020-05-18 2023-06-01 Biosion Inc. Antibodies binding il6r and uses thereof
WO2022005321A1 (en) 2020-06-29 2022-01-06 Federal State Budgetary Institution Scientific center of biomedical technologies of Federal Medical and Biological Agency Inhaled tocilizumab for treating interleukin-6 related respiratory diseases
KR20220028972A (ko) 2020-08-31 2022-03-08 (주)셀트리온 안정한 약제학적 제제
WO2022060412A1 (en) 2020-09-17 2022-03-24 Genentech, Inc. Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
AU2022232856A1 (en) 2021-03-12 2023-10-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for treatment or prevention of myasthenia gravis
CN117980333A (zh) 2021-06-11 2024-05-03 基因泰克公司 用st2拮抗剂治疗慢性阻塞性肺疾病的方法
US20240404622A1 (en) 2021-10-08 2024-12-05 Chugai Seiyaku Kabushiki Kaisha Method for preparing prefilled syringe formulation
WO2023210670A1 (ja) 2022-04-26 2023-11-02 中外製薬株式会社 医薬製剤含有フィルター内蔵シリンジ
US20240190978A1 (en) 2022-11-15 2024-06-13 CSBioAsset LLC Compositions and methods for immunomodulatory bifunctional fusion molecules
TW202444922A (zh) 2023-03-31 2024-11-16 國立大學法人大阪大學 用於預測敗血症患者之預後的生物標記及其用途
CN121038814A (zh) 2023-04-14 2025-11-28 中外制药株式会社 用于稳定含蛋白质药物制剂的方法
WO2025198912A1 (en) 2024-03-21 2025-09-25 Hoffmann-La Roche Inc. Methods of treating myasthenia gravis
HUP2400216A1 (hu) 2024-04-17 2025-10-28 Richter Gedeon Nyrt N-terminális glutamint tartalmazó immunglobulinok tisztítására szolgáló eljárások

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4304583A (en) * 1980-06-02 1981-12-08 Corning Glass Works Process for drying optical waveguide preforms
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5082782A (en) 1988-12-27 1992-01-21 Worcester Polytechnic Institute Production of horseshoe crab amebocytes in vitro
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5216128A (en) * 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
DE122009000023I2 (de) * 1989-07-20 2010-12-16 Kishimoto Antikörper gegen menschlichen Interleukin-6-Rezeptor
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
FR2943539B1 (fr) 2009-03-31 2011-07-22 Ethypharm Sa Composition pharmaceutique comprenant un macrolide immunosuppresseur de la famille des limus.
EP2409607A1 (de) 2010-07-20 2012-01-25 Josef Kurz Schuhlöffel

Also Published As

Publication number Publication date
JP2008073049A (ja) 2008-04-03
US20050142635A1 (en) 2005-06-30
JP3913965B2 (ja) 2007-05-09
JP2000116391A (ja) 2000-04-25
EP0628639B1 (en) 1999-06-23
ES2134212T3 (es) 1999-10-01
AU5621396A (en) 1996-10-24
JP3616087B2 (ja) 2005-02-02
NL300383I1 (nl) 2009-06-02
AU668349B2 (en) 1996-05-02
EP0628639A4 (en) 1994-12-28
HUT70258A (en) 1995-09-28
WO1992019759A1 (fr) 1992-11-12
JP2004045433A (ja) 2004-02-12
JP3176598B2 (ja) 2001-06-18
JP2007082560A (ja) 2007-04-05
US5795965A (en) 1998-08-18
US5817790A (en) 1998-10-06
TW205553B (index.php) 1993-05-11
AU1674092A (en) 1992-12-21
AU692100B2 (en) 1998-05-28
US7479543B2 (en) 2009-01-20
ATE181575T1 (de) 1999-07-15
EP0628639A1 (en) 1994-12-14
JP2001083151A (ja) 2001-03-30
HU9303002D0 (en) 1994-01-28
JP3370324B2 (ja) 2003-01-27
HU218140B (hu) 2000-06-28
LU91556I2 (fr) 2009-06-24
NL300383I2 (nl) 2010-02-01
DE122009000019I1 (de) 2009-07-16
DE69229482D1 (de) 1999-07-29
RU2139351C1 (ru) 1999-10-10
DK0628639T3 (da) 2000-01-24
KR100249937B1 (ko) 2000-04-01
GR3031174T3 (en) 1999-12-31

Similar Documents

Publication Publication Date Title
DE69229482T2 (de) Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor
DE69129896T2 (de) Gegen cd3 gerichtete antikörper
DE69124387T2 (de) Rahmenbau-mutierte antikörper und ihre herstellung
DE69321218T2 (de) Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
DE69535243T2 (de) Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
DE69233153T2 (de) Humanisierte monoklonale antikörper
DE69031591T2 (de) Cd4-spezifischer rekombinanter antikörper
DE69838454T2 (de) Natürlicher menschlicher antikörper
DE69735596T3 (de) Humanisiertes immunglobulin gegen den alpha4beta7-integrin
RU2244720C2 (ru) Антитело igg с аффинностью связывания в отношении антигенного комплекса cd3, рекомбинантные нуклеиновые кислоты, кодирующие легкую и тяжелую цепи антитела, способ получения системы, способ получения антитела, способ лечения пациента
DE69229278T2 (de) Humanisierter b-b10, ein anti-il-2-rezeptor-antikörper
DE69530763T2 (de) Antikörper gegen e-selektin
DE69636748T2 (de) Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien
DE69119211T2 (de) Cdr-gepfropfte anti-cea-antikörper und ihre herstellung
DE69429095T2 (de) Humanisierte antikoerper
DE69233482T2 (de) Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE69100768T2 (de) CD25-bindende Moleküle.
DE68909441T2 (de) Modifizierte Antikörper.
DE3751004T2 (de) Chimärer Antikörper mit Spezifität für menschliches Tumor-Antigen.
DE69419721T2 (de) Rekombinante anti-vla4 antikörpermoleküle
DE69233204T2 (de) Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
JPWO1992019759A1 (ja) ヒトインターロイキン−６受容体に対する再構成ヒト抗体
DE69331735T2 (de) Gegen das A33 Antigen gerichtete Humanisierte Antikörper
DE69504959T2 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
DE60226253T2 (de) Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers